Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › OH › Dublin › NPI 1932184322
Lab

Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings was paid $617.02M by Medicaid between Jan 2018 and Dec 2024, across 566 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 10% of everything it billed.

33Billing provider infoLABORATORY CORPORATION OF AMERICA HOLDINGS
DUBLIN, OH 43016
33aNPI1932184322assigned 12/08/2005
33bProvider typeClinical Medical Laboratory
28Total paid$617.02M
24GClaims53,462,000
24DCodes billed566
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Ohio

Rank by total paid#1 of 116
Median peer was paid$313K
This provider vs. median1,974×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$5.0M$10M$15M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20185,541,487$57.30M
20196,168,640$66.25M
20206,648,674$84.06M
20219,000,405$119.19M
20228,919,542$108.62M
20239,359,792$101.56M
2024incomplete7,823,460$80.02M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 10% 921,196 802,422 $62.80M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 7.3% 1,241,898 1,112,473 $44.84M
80050 General health panel 4.6% 957,294 864,325 $28.39M
80053 Comprehensive metabolic panel 4.4% 3,831,698 3,441,905 $26.94M
84443 Thyroid stimulating hormone (TSH) 4.4% 2,431,035 2,202,706 $26.89M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 4.2% 1,790,274 1,614,330 $25.73M
80061 Lipid panel 4.0% 3,464,440 3,143,228 $24.59M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 3.4% 62,806 55,991 $20.96M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.8% 3,528,193 3,150,958 $17.15M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 2.7% 520,757 473,164 $16.40M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 2.6% 518,903 468,885 $16.27M
83036 Hemoglobin; glycosylated (A1C) 2.5% 2,794,998 2,530,469 $15.63M
554 more codes
86480 2.4% 344,705 $14.84M
80081 1.8% 211,607 $10.84M
80074 1.6% 369,050 $9.91M
86803 1.4% 822,490 $8.88M
87086 Culture, bacterial; quantitative colony count, urine 1.4% 1,376,635 $8.39M
82607 1.3% 928,814 $8.25M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 1.3% 505,318 $7.93M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.2% 333,856 $7.68M
84439 1.2% 1,207,246 $7.46M
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 1.2% 36,855 $7.29M
82746 <1% 619,168 $5.27M
83655 <1% 499,062 $4.90M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 140,671 $4.64M
87902 <1% 25,757 $4.21M
87536 <1% 69,601 $4.11M
84403 <1% 241,298 $4.10M
87522 Neg quan hep c or qual rna <1% 157,016 $4.10M
82728 <1% 514,692 $4.08M
86235 <1% 61,692 $4.06M
87340 <1% 429,165 $3.36M
84153 <1% 298,578 $3.35M
36415 Collection of venous blood by venipuncture <1% 1,702,047 $3.16M
85027 <1% 678,299 $3.08M
83550 <1% 508,379 $2.91M
86592 <1% 864,925 $2.80M
87186 <1% 437,612 $2.80M
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 60,457 $2.70M
83013 <1% 79,491 $2.59M
84702 <1% 278,234 $2.56M
87088 <1% 422,354 $2.50M
83540 <1% 573,364 $2.45M
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 21,268 $2.45M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 52,102 $2.44M
83001 <1% 169,845 $2.25M
87081 <1% 447,905 $2.16M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 21,536 $2.14M
86003 <1% 41,719 $2.11M
82570 <1% 593,364 $2.11M
84146 <1% 167,878 $2.09M
82043 <1% 573,916 $2.08M
84402 <1% 127,380 $2.07M
86706 <1% 254,407 $2.06M
87150 <1% 102,568 $2.02M
86038 <1% 226,133 $1.98M
86780 <1% 196,837 $1.97M
80048 Basic metabolic panel (calcium, ionized) <1% 379,432 $1.95M
82670 <1% 115,774 $1.93M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 16,559 $1.77M
83970 <1% 78,444 $1.73M
86787 <1% 158,190 $1.72M
86696 <1% 113,981 $1.70M
81001 <1% 740,318 $1.66M
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 36,202 $1.59M
84481 <1% 155,978 $1.58M
84436 <1% 344,815 $1.51M
87070 <1% 263,921 $1.49M
86704 <1% 171,764 $1.49M
83002 <1% 131,406 $1.47M
87077 <1% 296,319 $1.41M
83735 <1% 345,099 $1.41M
86769 <1% 36,200 $1.40M
86360 <1% 42,956 $1.21M
83880 <1% 70,164 $1.21M
82274 <1% 118,394 $1.16M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 17,467 $1.15M
84144 <1% 85,675 $1.06M
86695 <1% 107,321 $1.04M
86140 <1% 295,860 $1.02M
86762 <1% 116,111 $1.02M
84479 <1% 241,712 $1.00M
86376 <1% 110,619 $987K
86708 <1% 114,765 $934K
82950 <1% 254,442 $917K
81329 <1% 20,602 $916K
82784 <1% 94,135 $834K
83525 <1% 107,492 $814K
86850 <1% 135,513 $784K
86677 <1% 38,945 $728K
84480 <1% 80,795 $726K
83516 <1% 54,401 $721K
86665 <1% 32,660 $699K
87901 <1% 4,042 $698K
86705 <1% 78,690 $671K
84550 <1% 228,163 $669K
87480 <1% 41,899 $666K
86431 <1% 152,898 $663K
80076 <1% 123,841 $647K
82627 <1% 48,170 $640K
87510 <1% 41,715 $640K
86800 <1% 64,301 $634K
85652 <1% 309,279 $617K
87660 <1% 41,937 $611K
83690 <1% 129,611 $604K
86225 <1% 63,313 $578K
82951 <1% 59,742 $567K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 21,352 $551K
83021 <1% 42,860 $529K
86200 <1% 61,288 $523K
80055 <1% 15,251 $515K
86735 <1% 50,511 $499K
82248 <1% 162,778 $497K
83020 <1% 57,223 $495K
86361 <1% 34,581 $491K
82652 <1% 29,223 $485K
86618 <1% 32,984 $466K
82565 <1% 170,194 $461K
85610 <1% 168,743 $453K
87900 <1% 5,019 $448K
82150 <1% 102,661 $448K
86765 <1% 54,169 $443K
84450 <1% 156,943 $435K
84460 <1% 146,762 $433K
86147 <1% 12,249 $422K
84681 <1% 33,645 $417K
82105 <1% 37,543 $417K
87209 <1% 33,960 $413K
85018 <1% 203,943 $395K
87535 <1% 15,113 $392K
86160 <1% 28,964 $389K
80164 <1% 55,929 $386K
82550 <1% 93,540 $374K
82977 <1% 83,840 $366K
82533 <1% 34,637 $363K
87563 <1% 20,425 $352K
87906 <1% 3,828 $347K
87521 Neg quan hep c or qual rna <1% 14,547 $346K
87075 <1% 50,978 $345K
84520 <1% 146,817 $333K
85660 <1% 77,957 $327K
86317 <1% 39,882 $326K
82947 <1% 129,198 $322K
87255 <1% 13,851 $322K
86364 <1% 32,316 $315K
84075 <1% 122,036 $312K
84154 <1% 29,057 $307K
86709 <1% 43,974 $307K
86901 <1% 108,924 $302K
85014 <1% 154,746 $302K
82040 <1% 115,820 $299K
81596 <1% 13,751 $298K
82247 <1% 116,516 $295K
81003 <1% 165,098 $294K
85730 <1% 73,642 $292K
82310 <1% 115,875 $290K
83615 <1% 77,736 $284K
83721 <1% 52,286 $280K
82785 <1% 28,918 $276K
86900 <1% 108,906 $275K
86664 <1% 26,638 $274K
86334 <1% 20,337 $274K
82672 <1% 18,843 $270K
84156 <1% 119,806 $267K
84445 <1% 8,033 $259K
84155 <1% 124,141 $257K
87517 <1% 7,740 $256K
84703 <1% 46,867 $253K
85045 <1% 95,451 $252K
84425 <1% 18,663 $249K
86146 <1% 6,113 $246K
84100 <1% 90,359 $245K
83498 <1% 15,230 $244K
87427 <1% 28,426 $243K
82024 <1% 10,409 $241K
84295 <1% 101,727 $235K
84165 <1% 35,951 $234K
82435 <1% 101,161 $227K
82140 <1% 27,976 $223K
86870 <1% 11,993 $221K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 4,527 $218K
80069 <1% 43,831 $216K
86141 <1% 23,883 $215K
82378 <1% 20,297 $212K
87177 <1% 34,178 $209K
87045 <1% 28,371 $208K
81374 <1% 7,000 $207K
87650 <1% 12,140 $202K
86304 <1% 15,276 $201K
83921 <1% 16,814 $195K
80362 <1% 15,632 $192K
86008 <1% 6,903 $186K
84207 <1% 10,531 $177K
82330 <1% 20,183 $173K
86702 <1% 21,186 $169K
80348 <1% 25,071 $166K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 2,505 $166K
86255 <1% 19,445 $164K
80178 <1% 37,740 $157K
88185 <1% 625 $157K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 6,203 $157K
84270 <1% 12,317 $157K
81243 <1% 10,412 $154K
83090 <1% 16,459 $153K
86258 <1% 11,871 $152K
87529 <1% 5,119 $150K
82952 <1% 47,962 $150K
84132 <1% 58,773 $150K
84466 <1% 19,473 $149K
86231 <1% 19,794 $149K
87046 <1% 28,704 $148K
83521 <1% 7,182 $146K
86300 <1% 10,501 $146K
82465 <1% 47,029 $145K
85379 <1% 22,913 $145K
83520 <1% 16,274 $144K
80051 <1% 35,061 $143K
86593 <1% 45,859 $143K
86757 <1% 5,989 $138K
81257 <1% 2,533 $134K
87350 <1% 14,178 $130K
87324 <1% 16,244 $128K
86701 <1% 18,044 $128K
82374 <1% 56,262 $125K
83718 <1% 24,436 $124K
86663 <1% 10,853 $119K
82626 <1% 6,727 $114K
84305 <1% 7,610 $110K
82088 <1% 4,005 $110K
G0307 Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) <1% 24,414 $109K
86359 <1% 5,534 $107K
86707 <1% 12,262 $105K
81361 <1% 2,737 $105K
86341 <1% 5,516 $103K
82239 <1% 8,012 $102K
87338 <1% 8,585 $99K
82103 <1% 11,795 $98K
86060 <1% 19,186 $96K
84134 <1% 11,753 $95K
80185 <1% 12,963 $91K
83883 <1% 11,724 $90K
87493 <1% 3,897 $89K
80177 <1% 12,677 $88K
82172 <1% 7,843 $87K
87538 <1% 3,307 $86K
86617 <1% 4,324 $85K
86381 <1% 5,756 $84K
86301 <1% 6,824 $84K
82397 <1% 9,399 $81K
84432 <1% 7,273 $81K
82390 <1% 11,576 $80K
86645 <1% 7,111 $79K
81381 <1% 1,888 $78K
84630 <1% 10,647 $77K
84482 <1% 9,772 $77K
86644 <1% 8,116 $77K
86256 <1% 5,120 $74K
86336 <1% 5,218 $73K
83010 <1% 9,298 $72K
86694 <1% 7,197 $72K
82677 <1% 5,186 $71K
81255 <1% 2,914 $71K
80156 <1% 9,343 $67K
81251 <1% 2,897 $66K
86671 <1% 5,009 $65K
81200 <1% 2,922 $65K
81241 <1% 3,356 $64K
82164 <1% 6,802 $64K
85246 <1% 4,740 $64K
87184 <1% 11,448 $64K
80361 <1% 7,317 $64K
85245 <1% 4,699 $64K
87329 <1% 7,623 $63K
81330 <1% 2,896 $63K
84484 <1% 9,735 $63K
80197 <1% 10,172 $62K
86037 <1% 4,056 $62K
80349 <1% 8,628 $62K
86335 <1% 3,492 $62K
84410 <1% 1,903 $61K
84166 <1% 5,901 $61K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 1,052 $60K
86015 <1% 6,971 $58K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 24,807 $58K
86747 <1% 2,953 $55K
86308 <1% 14,549 $55K
81260 <1% 2,916 $54K
81290 <1% 2,891 $54K
82525 <1% 6,672 $54K
87101 <1% 9,887 $54K
86777 <1% 5,571 $53K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 3,470 $52K
84080 <1% 6,319 $52K
81242 <1% 2,892 $52K
82787 <1% 3,146 $51K
82668 <1% 5,187 $50K
83704 <1% 2,744 $50K
81401 <1% 1,464 $49K
82747 <1% 5,071 $48K
85240 <1% 4,717 $47K
86162 <1% 3,599 $47K
82731 <1% 997 $47K
84244 <1% 3,102 $46K
81490 <1% 1,210 $46K
82552 <1% 6,171 $46K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 2,502 $45K
82553 <1% 6,828 $45K
80353 <1% 8,485 $44K
80171 <1% 3,731 $43K
84590 <1% 6,100 $43K
87205 <1% 15,151 $43K
80165 <1% 6,236 $43K
86778 <1% 3,849 $43K
81209 <1% 2,917 $42K
80324 <1% 6,770 $42K
80299 <1% 2,730 $42K
86666 <1% 2,222 $42K
83014 <1% 6,655 $41K
82679 <1% 2,748 $41K
82157 <1% 2,065 $41K
81025 <1% 9,503 $40K
80354 <1% 8,091 $39K
84446 <1% 4,297 $39K
80359 <1% 7,456 $38K
80175 <1% 4,604 $37K
83527 <1% 4,119 $36K
83993 <1% 3,057 $36K
85007 <1% 14,073 $36K
80365 <1% 7,051 $36K
82104 <1% 4,094 $36K
82085 <1% 5,612 $36K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 2,766 $35K
85598 <1% 2,944 $35K
85060 <1% 3,823 $34K
80346 <1% 2,703 $34K
80159 <1% 4,318 $34K
81256 <1% 1,853 $34K
81500 <1% 454 $33K
87040 <1% 4,110 $33K
85613 <1% 4,430 $33K
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 7,489 $33K
86738 <1% 2,363 $32K
80358 <1% 6,666 $31K
87076 <1% 6,210 $31K
80373 <1% 6,561 $31K
80347 <1% 4,090 $30K
82985 <1% 3,563 $30K
86355 <1% 1,232 $30K
80372 <1% 6,400 $29K
84238 <1% 1,830 $29K
87799 <1% 1,981 $29K
84478 <1% 9,213 $29K
88262 <1% 364 $29K
83789 <1% 2,696 $29K
82166 <1% 1,995 $28K
86005 <1% 3,890 $28K
88230 <1% 466 $28K
83695 <1% 3,741 $28K
86337 <1% 2,139 $28K
81291 <1% 2,266 $27K
85048 <1% 15,134 $27K
82232 <1% 3,165 $26K
85041 <1% 12,580 $26K
80184 <1% 4,530 $26K
82575 <1% 3,781 $26K
82542 <1% 2,249 $26K
87481 <1% 777 $26K
87497 <1% 1,300 $25K
85306 <1% 1,926 $24K
85384 <1% 4,513 $24K
81240 <1% 1,506 $24K
87328 <1% 2,258 $23K
88189 <1% 487 $23K
80162 <1% 4,212 $23K
80202 <1% 3,166 $23K
89055 <1% 6,600 $22K
86357 <1% 973 $19K
87641 <1% 707 $19K
84202 <1% 2,094 $19K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 7,806 $19K
85004 <1% 5,255 $19K
84152 <1% 1,505 $18K
87206 <1% 5,003 $18K
80183 <1% 2,576 $17K
83835 <1% 1,371 $17K
82610 <1% 2,206 $17K
88184 <1% 638 $16K
86682 <1% 2,351 $16K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 488 $16K
87631 <1% 194 $16K
82955 <1% 2,537 $15K
83874 <1% 1,807 $15K
85670 <1% 3,068 $14K
83605 <1% 2,529 $14K
86340 <1% 1,546 $14K
82681 <1% 881 $14K
84255 <1% 891 $14K
87254 <1% 665 $14K
85597 <1% 1,337 $13K
82653 <1% 823 $13K
85303 <1% 1,323 $13K
87116 <1% 1,889 $12K
85300 <1% 1,467 $12K
83992 <1% 2,542 $12K
82340 <1% 3,002 $11K
83003 <1% 969 $11K
36416 <1% 5,870 $10K
G0475 Hiv antigen/antibody, combination assay, screening <1% 4,717 $10K
81479 Unlisted molecular pathology procedure <1% 317 $10K
85732 <1% 1,547 $10K
84300 <1% 3,709 $10K
84145 <1% 690 $10K
84597 <1% 1,129 $9K
82705 <1% 2,647 $9K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 39 $9K
80305 <1% 933 $9K
86036 <1% 1,484 $9K
86804 <1% 805 $9K
83935 <1% 2,172 $9K
87015 <1% 2,093 $9K
85049 <1% 3,303 $8K
83625 <1% 1,070 $8K
83930 <1% 1,962 $8K
80356 <1% 970 $8K
86880 <1% 2,133 $8K
80364 <1% 2,068 $8K
81270 <1% 289 $7K
87109 <1% 804 $7K
84140 <1% 587 $7K
80201 <1% 979 $7K
83088 <1% 417 $7K
87106 <1% 1,157 $7K
80158 <1% 726 $7K
80198 <1% 1,013 $6K
80366 <1% 2,524 $6K
85305 <1% 716 $6K
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 4,462 $6K
83519 <1% 595 $6K
86615 <1% 336 $6K
80360 <1% 2,265 $6K
80355 <1% 2,450 $6K
82180 <1% 929 $6K
80368 <1% 2,187 $5K
80326 <1% 2,172 $5K
87807 <1% 673 $5K
85302 <1% 598 $5K
80370 <1% 2,186 $5K
87230 <1% 439 $5K
82595 <1% 1,047 $5K
87420 <1% 600 $5K
80367 <1% 2,301 $5K
81206 <1% 89 $5K
86148 <1% 654 $5K
81015 <1% 2,220 $5K
87476 <1% 255 $5K
81207 <1% 90 $5K
80357 <1% 2,117 $5K
80337 <1% 2,083 $4K
86753 <1% 447 $4K
80371 <1% 2,070 $4K
80377 <1% 2,074 $4K
80341 <1% 2,057 $4K
80338 <1% 2,079 $4K
80331 <1% 2,057 $4K
80344 <1% 2,058 $4K
80334 <1% 2,059 $4K
P9603 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled <1% 3,774 $4K
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 33 $3K
81377 <1% 55 $3K
80186 <1% 358 $3K
84133 <1% 1,296 $3K
85705 <1% 340 $3K
87425 <1% 284 $3K
84206 <1% 234 $3K
80325 <1% 354 $3K
84260 <1% 156 $3K
82384 <1% 161 $3K
89060 <1% 542 $3K
86658 <1% 102 $3K
84591 <1% 472 $2K
87634 <1% 71 $2K
83825 <1% 268 $2K
80321 <1% 278 $2K
80414 <1% 66 $2K
82656 <1% 287 $2K
87210 <1% 282 $2K
80320 <1% 207 $2K
82642 <1% 166 $2K
89051 <1% 560 $2K
83785 <1% 134 $2K
87593 <1% 49 $2K
86356 <1% 100 $2K
81422 <1% 12 $2K
99001 <1% 243 $2K
86689 <1% 126 $2K
84378 <1% 249 $2K
82175 <1% 150 $1K
99199 Unlisted special service, procedure or report <1% 203 $1K
85549 <1% 122 $1K
82523 <1% 271 $1K
81002 <1% 645 $1K
84442 <1% 137 $1K
83631 <1% 131 $1K
81402 <1% 33 $1K
86215 <1% 138 $1K
82507 <1% 128 $1K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 22 $1K
84252 <1% 89 $1K
87496 <1% 45 $1K
84999 <1% 143 $992.24
87102 <1% 172 $970.50
87511 <1% 35 $954.55
85301 <1% 116 $939.25
86316 <1% 79 $857.26
81400 <1% 47 $843.72
82436 <1% 457 $801.90
83945 <1% 299 $792.22
P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge <1% 1,863 $786.26
84163 <1% 78 $747.84
87484 <1% 13 $688.81
87252 <1% 36 $670.05
82308 <1% 43 $637.21
80195 <1% 120 $626.41
84433 <1% 70 $621.48
80235 <1% 72 $607.49
88141 <1% 183 $571.01
81332 <1% 51 $565.99
82657 <1% 43 $524.40
86710 <1% 41 $501.16
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 35 $494.00
84560 <1% 376 $491.61
87625 <1% 12 $486.60
83915 <1% 79 $480.81
81383 <1% 14 $462.65
80157 <1% 56 $451.56
82107 <1% 12 $409.86
84105 <1% 318 $350.72
82010 <1% 74 $326.58
81338 <1% 14 $316.26
87486 <1% 16 $314.43
87581 <1% 16 $314.43
82540 <1% 105 $311.08
86606 <1% 14 $273.38
84540 <1% 134 $263.27
83986 <1% 316 $231.71
84392 <1% 119 $226.18
80145 <1% 13 $211.35
81219 <1% 13 $197.05
80203 <1% 26 $196.14
83529 <1% 26 $187.56
80345 <1% 22 $177.94
87468 <1% 15 $166.38
86022 <1% 16 $155.09
81050 <1% 119 $149.96
82615 <1% 90 $148.51
82608 <1% 12 $132.27
85220 <1% 15 $129.73
87207 <1% 38 $122.63
87899 <1% 15 $77.02
80323 <1% 12 $73.72
86041 <1% 14 $57.80
86161 <1% 15 $52.73
86309 <1% 13 $48.05
Z9999 0% 30 $0.00
80375 0% 25 $0.00
81327 0% 60 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILLIAMS, KIMBERLY (VP)
Same official

Other billing entities under WILLIAMS, KIMBERLY

Full network →
ProviderLocationPaid
Laboratory Corporation of America HoldingsBurlington, NC$1.44B
Laboratory Corporation of America HoldingsRaritan, NJ$717.47M
Laboratory Corporation of America HoldingsBirmingham, AL$289.12M
Laboratory Corporation of AmericaPhoenix, AZ$265.90M
Laboratory Corporation of America HoldingsBurlington, NC$264.26M
Laboratory Corporation of America HoldingsCharleston, WV$220.04M
Laboratory Corporation of AmericaSeattle, WA$186.69M
Laboratory Corporation of AmericaTampa, FL$171.13M
Laboratory Corporation of AmericaSan Diego, CA$147.14M
Laboratory Corporation of AmericaHouston, TX$103.81M
Laboratory Corporation of AmericaEnglewood, CO$77.80M
Laboratory Corporation of AmericaDallas, TX$77.42M
Laboratory Corporation of AmericaBurlington, NC$59.75M
Medtox Laboratories, INCSaint Paul, MN$47.72M
Laboratory Corporation of America HoldingsBurlington, NC$15.65M
Laboratory Corporation of AmericaSan Antonio, TX$11.67M
Tri-Cities Laboratory, LLCKennewick, WA$8.69M
Laboratory Corporation of America HoldingsMonroe, LA$3.39M
Laboratory Corporation of AmericaItasca, IL$3.37M
Laboratory Corporation of AmericaAlbany, NY$2.06M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.